Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
153 results about "Monoamine neurotransmitter" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Monoamine neurotransmitters are neurotransmitters and neuromodulators that contain one amino group connected to an aromatic ring by a two-carbon chain (such as -CH₂-CH₂-). Examples are dopamine, serotonin and epinephrine.
Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant
Aryl alkanol piperazine derivatives of the formula and pharmaceutical compositions comprising the same. Also disclosed are methods for treating depression using the pharmaceutical compositon. Compounds of the invention have excellent dual inhibitory actions to the uptake of the mono-amines neurotransmitter, good antidepressant activities and minor side effects.
Owner:SHANGHAI INST OF PHARMA IND
Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters
InactiveUS20120258994A1Improve the level ofIncrease ratingsBiocideNervous disorderMetaboliteMedicine
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and / or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
![Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/2b76e59b-93e8-4227-9e24-297ff8ce8302/US20120258994A1-20121011-D00001.png "Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters")
![Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/2b76e59b-93e8-4227-9e24-297ff8ce8302/US20120258994A1-20121011-D00002.png "Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters")
![Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/2b76e59b-93e8-4227-9e24-297ff8ce8302/US20120258994A1-20121011-D00003.png "Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters")
Owner:ETHISMOS RES INC
Tropane-derivatives, their preparation and use
Compounds of formula (a), (b), (c), or (d), or any mixture thereof, or a pharmaceutically-acceptable salt thereof;wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; R3 is -CH2-X-R', wherein X is O, S or NR'', wherein R'' is hydrogen or alkyl and R' is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, or -CO-alkyl; R4 is phenyl optionally substituted with halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl, or aryl; 3,4-methylenedioxyphenyl; benzyl optionally substituted with halogen, CF3, CH, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino nitro, heteroaryl, or aryl; heteroaryl optionally substituted with halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl, or aryl; or naphthyl optionally substituted with halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl, or aryl. The compounds are monoamine neurotransmitter, i.e., dopamine, serotonin, noradrenaline, reuptake inhibitors.
Owner:NEUROSEARCH AS
Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.
Owner:AUSPEX PHARMA INC
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
InactiveUS20080234257A1High crystallinityThe result is moreBiocideNervous disorderDiabetic retinopathyChemical synthesis
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and / or premature ejaculation are described.
Owner:ACADIA PHARMA INC
Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
InactiveUS20140206740A1Treating and preventing and alleviating and moderating disorderInhibiting norepinephrineBiocideAnimal repellantsSubstance abuserNeurotransmitter
The present invention relates to (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.
![Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/6216f665-5c97-476f-a46f-c1590bf6fcc7/US20140206740A1-20140724-D00001.png "Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters")
![Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/6216f665-5c97-476f-a46f-c1590bf6fcc7/US20140206740A1-20140724-D00002.png "Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters")
![Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/6216f665-5c97-476f-a46f-c1590bf6fcc7/US20140206740A1-20140724-D00003.png "Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters")
Owner:OTSUKA AMERICA PHARMA INC
Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
InactiveUS20050182090A1Reduce pruningEliminate side effectsBiocideNervous disorderTropaneDopamine agonist agent
The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one dopamine agonist or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
Owner:BOEHRINGER INGELHEIM PHARM KG
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Owner:ACADIA PHARMA INC
Preparation method of CdTe@SiO2 quantum dot surface monoamine neurotransmitter molecularly imprinted polymer
The invention discloses a preparation method of a CdTe@SiO2 quantum dot surface monoamine neurotransmitter molecularly imprinted polymer. The preparation method comprises the following steps of: synthesizing CdTe@SiO2 quantum dots in a water phase, carrying out rotary evaporation till water is completely volatized, and washing off unreacted substances by absolute ethyl alcohol; adding the obtained CdTe@SiO2 quantum dots to a pore-foaming agent, sequentially adding template molecules, functional monomers and a crosslinking agent after uniform ultrasonic dispersion, and stirring and reacting for 20 hours under the protection of N2; centrifuging a reaction liquid, discarding a supernatant, and washing obtained solids to remove the template molecules to obtain the CdTe@SiO2 quantum dot surface monoamine neurotransmitter molecularly imprinted polymer. The material synthesized by the method has the advantages that a quantum dot fluorescent probe is high in sensitivity and simple and convenient to detect and has the characteristics that the molecularly imprinted polymer is high in selectivity and affinity and can be directly used for determining monoamine neurotransmitters in biological fluids.
Owner:NANJING MEDICAL UNIV
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.
Owner:ACADIA PHARMA INC
Application of tetrahydrocurcumin in preparing antidepressant and method for preparing solid dispersion of tetrahydrocurcumin
The invention relates to application of tetrahydrocurcumin in preparing an antidepressant and a method for preparing a solid dispersion of the tetrahydrocurcumin. The invention aims to provide the application of the tetrahydrocurcumin to prepare the antidepressant. The tetrahydrocurcumin and a surfactant are mixed in certain proportion to obtain the solid dispersion of the tetrahydrocurcumin. The method for preparing the solid dispersion of the tetrahydrocurcumin comprises the following steps that: according to the weight ratio of 1:3-1:30, the tetrahydrocurcumin and the surfactant are heated until completely melted, frozen in a low-temperature environment, and taken out, dried and crushed to obtain the solid dispersion of the tetrahydrocurcumin. The tetrahydrocurcumin and the solid dispersion of the tetrahydrocurcumin are used for preparing drugs, health care products, foods or food additives of relieving mental depression. The tetrahydrocurcumin has the function of relieving mental depression, and the function of the tetrahydrocurcumin is possibly related with the influence on a monoamine neurotransmitter system; moreover, compared with fluoxetine, the tetrahydrocurcumin has the advantages of low toxicity and good curing effect.
Owner:FUJIAN MEDICAL UNIV
Detecting method for determining various neurotransmitters on the basis of in situ derivation
ActiveCN105866303AHigh detection sensitivityHigh selectivityComponent separationChemical structureCarboxylic acid
Owner:山东住融物业有限公司
Application of acetagastrodine in preparing medicines to prevent and treat vascular dementia (VD) and Alzheimer disease (AD)
Relating to the medicine field, the invention discloses the use of acetagastrodine in preparing medicines to prevent and treat vascular dementia and Alzheimer disease. The invention also provides a medicinal composition for preventing and treating senile dementia and its capsule as well as sustained release agent. Animal tests show that: acetagastrodine can substantially enhance the learning and memory abilities of rats with vascular dementia, reduce the activity of AchE in brains, enhance the vitality of ChAT in brains, and remarkably reduce Glu content; acetagastrodine has significant protective effect on damaged PC12 cells caused by H2O2 by enhancing the vitality of SOD and total ATP enzyme in PC12 cells and reducing the content of MDA and LD; acetagastrodine can substantially enhance the learning and memorizing abilities of AD model rats, enhance the CAT content in brains of the model rats, reduce the MAO vitality and simultaneously prevent the decrease of neurotransmitters. Acetagastrodine is better than gastrodin in terms of the treatment effects on VD and AD, and enjoys good clinical application prospect.
Owner:KPC PHARM INC
Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
InactiveUS20050182089A1Eliminate side effectsReduce pruningBiocideNervous disorderNR1 NMDA receptorTropane
Accordingly, the invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one NMDA receptor antagonists or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
Owner:NEUROSEARCH AS
Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
InactiveUS20140228421A1Great extracellular levelGood treatment effectBiocideOrganic chemistryReuptake inhibitorMonoamine neurotransmitter
The present invention relates to methods of inhibiting native and promiscuous uptake of biogenic amine neurotransmitters with triple reuptake inhibitors in the treatment of conditions affected by monoamine neurotransmitters.
Owner:ETHISMOS RES INC
Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.
Owner:AUSPEX PHARMA INC
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.
Owner:ACADIA PHARMA INC
Pharmaceutical composition for preventing and treating Parkinson's disease and preparation method thereof
ActiveCN103720959ALess medicinalImprove quality controlNervous disorderUnknown materialsTyrosine hydroxylaseBULK ACTIVE INGREDIENT
The invention relates to a pharmaceutical composition for preventing and treating Parkinson's disease. The pharmaceutical composition consists of active ingredients and medically acceptable auxiliary materials, and is characterized in that the active ingredients consist of the following components in percentage by weight: rhizoma acori graminei volatile oil extracted from rhizoma acori graminei accounting for 25-45 percent and tortoise plastron water extract extracted from tortoise plastron accounting for55-75 percent. By adopting the pharmaceutical composition, neurological integrals of Parkinson's model rats can be obviously improved, the content of monoamine neurotransmitters in rat brains is increased, reduction of tyrosine hydroxylase in brain is inhibited, and the effect of preventing and treating the Parkinson's disease is obvious.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
InactiveUS20050154009A1Eliminate side effectsReduced effectivenessBiocideNervous disorderCholinesterase inhibitionAdditive ingredient
The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one acetylcholinesterase inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
Owner:NEUROSEARCH AS
Detection method for determining monoamine neurotransmitters based on derivatization
ActiveCN107449841ADerivatization reaction conditions are simpleSimple derivation stepsComponent separationLower limitDerivatization
The invention discloses a detection method for determining monoamine neurotransmitters based on derivatization. According to the detection method, the monoamine neurotransmitters and derivative reagent n-butanal and the like generate derivative reaction, and an obtained derivatization product is analyzed and detected by an ultrahigh-phase liquid chromatogram-mass spectrum combined system; the monoamine neurotransmitters include dopamine, noradrenaline and 5-hydroxytryptamine. Derivatization reaction conditions of the method have the advantages of simpleness, gentleness, quickness and environmental friendliness; the method can process samples in batch and has the advantages of high analyzing speed, low analyzing method quantitative lower limit and good linear range, precise and accuracy; simultaneous quantitative analysis on the dopamine, the noradrenaline and the 5-hydroxytryptamine in trace rat brain microdialysate is achieved.
Owner:上海药明康德新药开发有限公司
Functional food for improving senile dementia
The invention relates to a functional food for improving senile dementia in the field of functional foods. The functional food is prepared from the following raw materials: 10 to 50 parts of deep sea fish oil, 5 to 80 parts of grape pip, 10 to 70 parts of ginkgo leaf and 5 to 40 parts of anemarrhena. The deep sea fish oil is heated to the temperature of between 35 and 45 DEG C, and is added with dry extract powder prepared by extracting defatted grape pip, ginkgo leaf and anemarrhena, and the mixture is stirred, ground uniformly and filled. The functional food prepared from a few raw materials by a simple process can improve the content of catalase (CAT) in brain, reduce the activity of monoamine oxidase (MAO), antagonize oxidation reaction and prevent the reduction of monoamine neurotransmitter so as to achieve the effect of preventing and treating the senile dementia; in the aspect of preventing and treating alzheimer disease (AD), the functional food has the advantages of conditioning integrally and acting at multiple target spots; and after the functional food is prepared into capsules, the capsules are convenient to eat and store, long in quality guarantee period, attractive in appearance, easy to produce and high in bioavailability, and better realize the health-care function to benefit consumers.
Owner:济南老来寿生物集团股份有限公司
Aralkyl-alcohol peiperazine derivatives and their uses as antidepressant
Aryl alkanol piperazine derivatives of the formulaand pharmaceutical compositions comprising the same. Also disclosed are methods for treating depression using the pharmaceutical composition. Compounds of the invention have excellent dual inhibitory actions to the uptake of the mono-amines neurotransmitter, good antidepressant activities and minor side effects.
Owner:SHANGHAI INST OF PHARMA IND CO LTD
Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
This invention relates to chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors.In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Owner:INITIATOR PHARMA AS
Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
This invention relates to novel chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors.In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Owner:NEUROSEARCH AS
Lily bulb and rhizoma rehmanniae soup standard decoction with anti-depression function and preparing method and application thereof
The invention belongs to the field of traditional Chinese medicine, and particularly relates to a preparing method of a lily bulb and rhizoma rehmanniae soup standard decoction with an anti-depressionfunction. Firstly, records about dosages of a classical prescription lily bulb and rhizoma rehmanniae soup, production places of geo-authentic crude drugs and preparing methods of the classical prescription are looked up in the literature of past dynasties, and then the classical prescription lily bulb and rhizoma rehmanniae soup standard decoction is prepared; after the lily bulb and rhizoma rehmanniae soup is intervened in, the content of monoamine neurotransmitters 5-HT, NE and DA is increased, the content of inhibitory neurotransmitters is lowered, and the content of excitatory neurotransmitters is increased; finally, a high performance liquid chromatograph is utilized for analyzing the active ingredients for the drug effect of the decoction, a modern scientific basis is provided forthe depression treatment function mechanism and drug-using formula of the classical prescription lily bulb and rhizoma rehmanniae soup, and the decoction has high theoretical significance and clinicalvalue.
Owner:SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
Application of swertisin and derivative thereof
The invention provides a novel application of swertisin and a derivative thereof in preparing an antidepressant drug. The swertisin has an obvious antidepressant effect, can significantly improve functions of a monoamine neurotransmitter system, has an auxiliary therapeutic effect for depression and symptoms thereof, and provides a novel selection for treating depression clinically.
Owner:SICHUAN ACAD OF CHINESE MEDICINE SCI
Tropane-derivatives, their preparation and use
Compounds of formula (a), (b), (c), or (d), or any mixture thereof, or a pharmaceutically-acceptable salt thereof; wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; R3 is -CH2-X-R', wherein X is O, S or NR'', wherein R'' is hydrogen or alkyl and R' is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, or -CO-alkyl; R4 is phenyl optionally substituted with halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl, or aryl; 3,4-methylenedioxyphenyl; benzyl optionally substituted with halogen, CF3, CH, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl, or aryl; heteroaryl optionally substituted with halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl, or aryl; or naphthyl optionally substituted with halogen, CF3, CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl, or aryl. The compounds are monoamine neurotransmitter, i.e., dopamine, serotonin, noradrenaline, reuptake inhibitors.
Owner:NEUROSEARCH AS
Composite, preparation thereof and application of composite in preparing antidepressant drug
ActiveCN103565781ANervous disorderHydroxy compound active ingredientsPositive controlAntidepressants drugs
The invention relates to a composite which is composed of (2Z, 8Z, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4) or is composed of (2Z, 8Z, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4). The composite disclosed by the invention is obtained by being extracted and separated from traditional Chinese medicine radix bupleuri. The result of an in-vitro monoamine neurotransmitter reuptake inhibition experiment shows that the composite disclosed by the invention has triple inhibition effects on the reuptake of 5-HT (5-Hydroxytryptamine), NA (noradrenalin) and DA (Dopamine), is higher than the effective part of ease powder petroleum ether and the part of radix bupleuri petroleum ether in inhibition ratio and is higher than positive control drugs, namely fluoxetine, norpramin and 6-hydroxydopamine, in inhibiting effect. According to the invention, two composites can be applied to prepare a drug used for preventing and curing depression.
Owner:SHANXI UNIV
Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
InactiveUS20140039029A1Improve the level ofIncrease ratingsBiocideNervous disorderMetaboliteMedicine
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and / or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
![Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters](https://images-eureka.patsnap.com/patent_img/86e54128-cac6-436d-9880-fa6475ebd150/US20140039029A1-20140206-D00001.png "Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters")
![Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters](https://images-eureka.patsnap.com/patent_img/86e54128-cac6-436d-9880-fa6475ebd150/US20140039029A1-20140206-D00002.png "Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters")
![Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters](https://images-eureka.patsnap.com/patent_img/86e54128-cac6-436d-9880-fa6475ebd150/US20140039029A1-20140206-D00003.png "Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters")
Owner:ETHISMOS RES INC
Application of forsythin to preparation of medicine for improving cognitive function and treating Alzheimer's diseases
InactiveCN102784160AImprove health qualityImprove the quality of lifeOrganic active ingredientsNervous disorderDiseaseLife quality
The invention discloses novel application of forsythin belonging to active components of natural medicinal plants, and particularly relates to application of forsythin as the only active ingredient to preparation of a medicine for improving a cognitive function and treating Alzheimer's diseases. Animal and cell research results indicate that the forsythin has the exact function of improving the cognitive function and can remarkably improve the spatial learning and memory ability of animals in an aging and Alzheimer's disease model, the level of a center monoamine neurotransmitter of an old-aged animal is increased, the genetic expression of presenilin 2 in a rat brain of an Alzheimer's disease model is reduced, and the survival rate of neuroblastoma cells induced by beta-amyloid protein is increased. The forsythin is matched with relevant auxiliary materials, a health care product or a medicine for purposefully improving the cognitive function and treating the Alzheimer's diseases can be prepared by a conventional preparation method, and the health care product and the medicine can be used for delaying and improving relevant diseases of cognitive hypofunction such as the course of the Alzheimer's diseases, enhancing the healthy quality and the life quality of old people and realizing a healthy aging social value.
Owner:SUZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com